CELG Celgene Corp. Common Stock

Ownership history in BB BIOTECH AG  ·  70 quarters on record

This page tracks every 13F SEC filing in which BB BIOTECH AG reported a position in Celgene Corp. Common Stock (CELG). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
28.36% (2009 Q3)
Avg. % of fund
15.85%
First filed
2000 Q1
Last filed
2019 Q1
Quarters held
70
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2019 Q1 REDUCED 2,200,000 -103,875 -4.5% 5.22% $207.5M
2018 Q4 REDUCED 2,303,875 -680,423 -22.8% 4.73% $147.7M
2018 Q3 REDUCED 2,984,298 -340,000 -10.2% 7.07% $267.1M
2018 Q2 UNCHANGED 3,324,298 0% 7.62% $264.0M
66 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding CELG

As of 2025 Q1 — sorted by position size

Heck Capital Advisors, LLC 0.11%
← Back to BB BIOTECH AG Holdings